The 6K was the money Gartner gave to Radient to get the IP for DR70. Provista had nothing to do with that.
That is how Gartner got his hands on the IP that he is now using to manufacture and sell DR-70. Gartner is still calling it "The Lung Cancer Test" on his website and on Fundable.com. In the PR (link below) he is calling it "The Lung Cancer Test for Early Detection."
The USPTO rejected his request for a Trademark on "Lung Cancer Test" so he abandoned that name, and now he's trying a different name in his PR, but who cares what he calls it and who cares what name, if any, he finally gets Trademarked? The point about GCDx is: Provista is not involved and Radient is not involved. Gartner is on his own and he does not have much funding -- he's hosting on GoDaddy, he's using PayPal to accept credit cards, whoever is building his website is an amateur by allowing test pages to appear to the public, and GCDx is trying to get money through crowdsourcing (Fundable). Everything about GCDx screams "mom and pop."
Now the GCDx clickable link to "order one right through our store" goes to a 404 error File Not Found. That GCDx website is a farce.
The facts say "no takeover." Wishful thinking says "there has to be a takeover because MacLellan has options priced at 11 cents." This will continue for three more months but on or before the end of 2014, the following will have occurred:
1. The patent application will change status to ABANDONED. 2. The new Provista website will undoubtedly be online without any mention of Radient or GCDx.
How will the Takeover rumor adapt to accommodate those new uncomfortable facts? No worries mate, the takeover rumor will apparently never die -- it's managed to get past far more damaging facts than those. When a rumor is based on absurdity there's no killing it.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.